Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Neville F. Ford"'
Autor:
Neville F. Ford
Publikováno v:
The Journal of Clinical Pharmacology. 56:1474-1483
The major metabolic pathway of clopidogrel is conversion to carboxylic acid by an esterase (CES1), forming clopidogrelic acid (SR26334) that is inactive. There is agreement on the structure of the active metabolite; however, there are differing views
Autor:
Neville F Ford
Publikováno v:
Journal of Pharmacology and Pharmacotherapeutics. 9:165-166
Autor:
Dirk Taubert, Neville F. Ford
Publikováno v:
The Journal of Clinical Pharmacology. 53:241-248
It has been presumed that CYP2C19 has a major role in the metabolism of clopidogrel. This presumption has been based on in vitro drug metabolism studies using microsomes from baculovirus infected insect cells (BD-Supersomes™). If clopidogrel were p
Autor:
Neville F. Ford
Publikováno v:
The Journal of Clinical Pharmacology. 54:881-883
Autor:
Neville F. Ford
Publikováno v:
The Journal of Clinical Pharmacology. 49:506-512
Clopidogrel is important for the management of acute coronary syndromes and, along with aspirin, is recommended in the American College of Cardiology/American Heart Association guideline. It is also used along with aspirin, during the placement of co
Autor:
Neville F. Ford, Neil R. Johnston, Neeraj Dhaun, David J. Webb, Maria Palmisano, David E. Newby, Janis L. Hammett, Fiona E. Strachan
Publikováno v:
British Journal of Clinical Pharmacology. 60:611-622
Aims A number of endothelin receptor antagonists (ERAs) are currently in clinical development as potential therapies in states characterized by vasoconstriction, such as systemic hypertension. We investigated the haemodynamic effects of locally and s
Autor:
Howard Uderman, BN Swanson, Neville F. Ford, Irene Ferreira, Ole Vesterqvist, Wei‐chi Liao, Carol L. Delaney, Mohammed Jemal
Publikováno v:
British Journal of Clinical Pharmacology. 56:395-406
Aims To determine the pharmacokinetics, pharmacodynamics and tolerability of omapatrilat, a vasopeptidase inhibitor, in healthy subjects. Methods The effects of oral omapatrilat were evaluated in healthy men in two double-blind, placebo-controlled, d
Publikováno v:
Current Therapeutic Research. 62:699-708
Background: Behavioral evidence from animal studies has suggested that ceronapril and other angiotensin-converting enzyme (ACE) inhibitors have some anxiolytic activity. Objectives: The objectives of this trial were to assess the effects of ceronapri
Autor:
Maria R. Marino, Frank Tenney, Peter H. Slugg, Neville F. Ford, John J. Stewart, Abdullah Sakarcan, Kim G. Adcock, Ophelia W. Hadjilambris, Nimish N. Vachharajani, John T. Wilson, Thomas G. Wells
Publikováno v:
The Journal of Clinical Pharmacology. 41:742-749
An open-label study was conducted to characterize the pharmacokinetics and antihypertensive response to irbesartan in children (1-12 years) and adolescents (13-16 years) with hypertension. Patients received single once-daily oral doses of irbesartan
Autor:
Stanford S. Jhee, Neville F. Ford, I. Edgar Fulmor, John J. Sramek, Daniel E. Salazar, Neal R. Cutler, Robert A. Smith
Publikováno v:
Headache: The Journal of Head and Face Pain. 38:446-452
Avitriptan (BMS-180048) is a 5-HT1-like receptor agonist for the treatment of migraine. This double-blind, placebo-controlled, randomized, parallel-group study evaluated the pharmacokinetics, safety, and preliminary efficacy of avitriptan in patients